Literature DB >> 25292485

Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.

Daniel A Heinrich1, Marc Weinkauf, Grit Hutter, Yvonne Zimmermann, Vindi Jurinovic, Wolfgang Hiddemann, Martin Dreyling.   

Abstract

Entities:  

Keywords:  anti-CD20; mantle cell lymphoma; monoclonal antibodies; obinutuzumab; rituximab

Mesh:

Substances:

Year:  2014        PMID: 25292485     DOI: 10.1111/bjh.13132

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

Authors:  Andrew Grigg; Martin J S Dyer; Marcos González Díaz; Martin Dreyling; Simon Rule; Guiyuan Lei; Andrea Knapp; Elisabeth Wassner-Fritsch; Paula Marlton
Journal:  Haematologica       Date:  2016-12-23       Impact factor: 9.941

Review 2.  Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.

Authors:  Fengting Yan; Ajay K Gopal; Solomon A Graf
Journal:  Pharmaceuticals (Basel)       Date:  2017-03-10

Review 3.  Emerging therapies in mantle cell lymphoma.

Authors:  Walter Hanel; Narendranath Epperla
Journal:  J Hematol Oncol       Date:  2020-06-17       Impact factor: 17.388

Review 4.  New Treatment Options in Advanced Stage Follicular Lymphoma.

Authors:  Kai Hübel; Gilles Salles; Robert Marcus; Pier Luigi Zinzani; Martin Dreyling
Journal:  Hemasphere       Date:  2018-11-28

Review 5.  Controversies in the Treatment of Follicular Lymphoma.

Authors:  Kai Hübel; Michele Ghielmini; Marco Ladetto; Ajay K Gopal
Journal:  Hemasphere       Date:  2020-01-10

6.  Up-regulation of microRNA-497 inhibits the proliferation, migration and invasion but increases the apoptosis of multiple myeloma cells through the MAPK/ERK signaling pathway by targeting Raf-1.

Authors:  Cheng-Yu Ye; Cui-Ping Zheng; Wei-Wei Ying; Shan-Shan Weng
Journal:  Cell Cycle       Date:  2018-12-11       Impact factor: 4.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.